BIIB

Biogen Inc

250.69

Oct 23 • 3:59 PM ET -3.15 (-1.24%)

246.01

Aftermarket • 7:30 PM ET -4.68 (-1.87%)

Healthcare Drug Manufacturers - General USA Large NASD

Peers: NVS LLY SNY AMGN IONS GILD ARGX REGN SRPT SUPN

| Held by: VTI VOO VO IVV SPY VTV IBB XLV RSP VOE

Index	S&P 500
Market Cap	37.04B
Enterprise Value	44.11B
Income	834.60M
Sales	9.66B
Book/sh	127.61
Cash/sh	8.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	7500
IPO	Sep 17, 1991

P/E	44.40
Forward P/E	15.28
PEG	2.27
P/S	3.83
P/B	1.96
P/C	28.83
P/FCF	13.74
EV/EBITDA	16.18
EV/Sales	4.57
Quick Ratio	1.26
Current Ratio	1.87
Debt/Eq	0.44
LT Debt/Eq	0.40
Option/Short	Yes / Yes

EPS (ttm)	5.65
EPS next Y	16.41
EPS next Q	1.97
EPS this Y	-19.21%
EPS next Y	32.93%
EPS next 5Y	6.74%
EPS past 3/5Y	-25.04% -18.74%
Sales past 3/5Y	0.35% -5.06%
EPS Y/Y TTM	-45.79%
Sales Y/Y TTM	0.53%
EPS Q/Q	-84.85%
Sales Q/Q	2.38%
Earnings	Oct 28 BMO
EPS/Sales Surpr.	22.49% 11.20%

Insider Own	0.75%
Insider Trans	-0.11%
Inst Own	98.74%
Inst Trans	3.13%
ROA	2.76%
ROE	4.58%
ROIC	3.16%
Gross Margin	64.29%
Oper. Margin	19.50%
Profit Margin	8.64%
SMA20	8.56%
SMA50	12.23%
SMA200	25.69%
Trades

Shs Outstand	147.70M
Shs Float	146.64M
Short Float	4.07%
Short Ratio	5.80
Short Interest	5.97M
52W High	254.41 -1.46%
52W Low	138.00 81.66%
Volatility	3.14% 2.76%
ATR (14)	6.98
RSI (14)	70.59
Beta	0.12
Rel Volume	1.12
Avg Volume	1.03M
Volume	1,157,376

Perf Week	7.75%
Perf Month	10.75%
Perf Quarter	25.26%
Perf Half Y	35.96%
Perf YTD	42.45%
Perf Year	67.04%
Perf 3Y	-1.07%
Perf 5Y	-5.33%
Perf 10Y	-6.36%
Recom	1.84
Target Price	247.55
Prev Close	253.84
Price	250.69
Change %	-1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Upgrade	JP Morgan	Neutral → Overweight	$300
Aug-13-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$300
Jul-13-26	Upgrade	Truist	Hold → Buy	$235
Jun-08-26	Upgrade	Needham	Hold → Buy	$255
May-15-26	Resumed	Evercore ISI	Outperform
Apr-22-26	Upgrade	UBS	Neutral → Buy	$225
Apr-20-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$250
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$214
Feb-20-26	Initiated	Barclays	Equal Weight	$185
Feb-09-26	Reiterated	H.C. Wainwright	Buy	$194 → $228
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164

Show Previous Ratings

Oct-22-26 01:08PM	The Week Ahead: Wall Street Awaits October Fed Decision (Schaeffer's Research) +5.34%
08:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates (Business Wire)
Oct-20-26 03:27PM	RBC Capital names top healthcare stocks as sector upgraded to overweight (Investing.com)
Oct-19-26 07:30AM	Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-16-26 01:46PM	Another Biotech IPO Pops on Rough Day for Broader Market (Barrons.com)
06:30AM	Loading…
06:30AM	Biogen-backed Estuary nabs $93M for kidney disease gene therapy (BioPharma Dive)
Oct-12-26 12:37PM	Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning. (Barrons.com)
09:49AM	3 Big Names Enjoying Renewed Analyst Backing (Schaeffer's Research)
09:41AM	Salesforce upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
07:51AM	JPMorgan gets bullish on Biogen ahead of 2027 catalysts (Investing.com)
07:33AM	BIIB Stock: JPMorgan Sees Increasingly Compelling Catalyst Path For Biogen, Raises Price Target To $300 (Stocktwits)
Oct-06-26 01:06PM	Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says (Proactive)
Oct-02-26 11:20AM	Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus (GlobeNewswire)
Sep-29-26 12:23AM	Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? (Stocktwits)
Sep-23-26 04:01PM	Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization (Business Wire)
08:41AM	Loading…
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
Sep-21-26 11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
Sep-17-26 04:15PM	Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN (GlobeNewswire)
Sep-16-26 02:00AM	LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Approved in Japan for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Sep-04-26 12:13PM	This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. (Barrons.com)
Sep-03-26 07:30PM	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (GlobeNewswire)
12:00AM	LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China (GlobeNewswire)
Sep-02-26 08:00AM	Stoke Therapeutics to Present at the Cantor Global Healthcare Conference (Business Wire)
Sep-01-26 10:00AM	Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress (InvestorsHub)
07:30AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (GlobeNewswire)
Aug-31-26 07:30PM	Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (lecanemab) for Early Alzheimer's Disease (GlobeNewswire)
Aug-27-26 01:01AM	Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ... (GuruFocus.com)
Aug-24-26 08:04AM	LEQEMBI IQLIK (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease (GlobeNewswire)
Aug-19-26 12:32PM	Real Parkinsons Disease Hope from Jupiter Neurosciences (Exec Edge)
Aug-13-26 09:52AM	Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation (Investing.com)
06:15PM	Loading…
Aug-06-26 06:15PM	Biogen Completes Acquisition of RayThera Inc. (GlobeNewswire)
Aug-05-26 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Aug-03-26 04:01PM	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-29-26 05:03PM	Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ... (GuruFocus.com)
01:22PM	Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views (Investor's Business Daily)
08:16AM	Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher (InvestorsHub)
07:13AM	Earnings roundup: Biogens resiliency, AstraZenecas growth pitch and GSKs oncology push (BioPharma Dive)
06:45AM	Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales (Investing.com)
06:23AM	Biogen Cuts FY Adjusted View as Profit Declines (The Wall Street Journal)
06:02AM	Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs (Barrons.com)
Jul-27-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates (Business Wire)
Jul-20-26 12:15PM	VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform (Exec Edge)
Jul-16-26 12:18PM	Slate Medicines Appoints Mark W. Hahn to Board of Directors (Exec Edge) +5.92%
07:47AM	Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide (PR Newswire)
Jul-15-26 11:23AM	Acumen Pharmaceuticals Shows Early Alzheimers Disease Insights (Exec Edge)
08:15AM	Biogen Appoints Michael J. Parini as Chief Legal Officer (GlobeNewswire)
07:25AM	AAIC26: Biogen stock drops after unveiling tau-targeting ASO data (Clinical Trials Arena)
Jul-14-26 02:38PM	BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimers Drug Benefits Will Replicate In Further Study (Stocktwits) -8.17%
02:09PM	Biogen's Alzheimer's Drug Leaves Questions Unanswered, and That's a Problem (Barrons.com)
01:40PM	Biogen stock sinks after Alzheimer's drug trial data fails to impress investors (Quartz)
01:36PM	Biogen stock falls 8% on Alzheimer's drug diranersen trial data (Quartz)
12:12PM	Biogen Stock Sinks on Lackluster Alzheimer's Results (The Wall Street Journal)
12:01PM	Biogen tumbles 8.7% as breakthrough Alzheimers data is clouded by dosing paradox (Investing.com)
11:18AM	LEQEMBI Real-World LEADER Study Presented at AAIC 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment (GlobeNewswire)
09:48AM	Biogen Shares Rise After Positive Phase 2 Alzheimer's Trial Results (BIIB) (InvestorsHub)
09:19AM	Can Biogen Score Another Win In Alzheimer's Disease? (Investor's Business Daily)
09:15AM	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease (GlobeNewswire)
Jul-13-26 05:38PM	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease (GlobeNewswire)
04:30PM	Biogen Inc. stock outperforms competitors on strong trading day (MarketWatch)
03:21PM	BIIB Stock Jumps 5% Analysts Raise Price Targets After FDA Clears Alzheimers Treatment For At-Home Use (Stocktwits)
09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly)
08:31AM	Truist upgrades Biogen to Buy on Alzheimers, pipeline optimism ahead of key data (Investing.com)
08:15AM	Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details (Barrons.com)
07:30AM	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer (Business Wire)
02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
Jul-12-26 11:18AM	LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 (GlobeNewswire)
Jul-10-26 07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-07-26 05:39AM	Vertex to acquire Crinetics in $10B foray into endocrine disease drugs (BioPharma Dive)
Jul-06-26 02:04PM	3 Healthcare ETFs to Own in a Choppy Stock Market (Barrons.com)
Jul-02-26 07:53PM	BIIB Stock Ends 3% Higher Why This Strategist Picks Biogen Over Other Biotech Peers (Stocktwits)
Jun-29-26 07:42AM	Biogen trims Apellis pipeline and R&D team after $5.6bn takeover (Pharmaceutical Technology)
06:59AM	Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen (GlobeNewswire)
Jun-26-26 04:30PM	Biogen Inc. stock outperforms competitors on strong trading day (MarketWatch) +6.97%
01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com)
Jun-19-26 05:48AM	Biogen to acquire RayThera for up to $1bn (Pharmaceutical Technology)
Jun-18-26 09:40AM	Biogen acquires RayThera in deal worth up to $1 billion (Quartz)
07:12AM	Biogen adds more immune drugs in $1B buyout of secretive startup RayThera (BioPharma Dive)
Jun-17-26 08:03PM	BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal (Stocktwits)
06:59PM	Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. (GlobeNewswire)
Jun-16-26 06:18PM	Acumen Nominates 2 Therapies to Treat Alzheimers Disease (Exec Edge)
Jun-05-26 06:05AM	Biogen's salanersen gains FDA breakthrough therapy designation for SMA (Pharmaceutical Business Review)
Jun-04-26 07:30AM	Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (GlobeNewswire)
01:00AM	EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus (GlobeNewswire)
Jun-03-26 07:30AM	Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses (GlobeNewswire)
03:30AM	Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. (Barrons.com)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
Jun-01-26 01:30AM	UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus (GlobeNewswire)
May-28-26 04:01PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire)
May-22-26 06:46AM	Parkinsons drug from Biogen, Denali comes up short (BioPharma Dive)
May-21-26 07:03PM	BIIB, DNLI Stocks Edge Lower After Hours: Parkinsons Drug Misses Key Goals In Trial (Stocktwits)
06:00PM	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease (GlobeNewswire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-15-26 09:45AM	Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Biogen completes $5.3B Apellis Pharmaceuticals acquisition (Quartz)
May-14-26 07:19PM	Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug (GuruFocus.com) -6.43%
04:30PM	Biogen Inc. stock underperforms Thursday when compared to competitors (MarketWatch)
01:03PM	Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery. (Investor's Business Daily)
10:08AM	Biogen Shares Surge After Positive Mid-Stage Alzheimers Trial Results (InvestorsHub)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Godbout Sean	Chief Accounting Officer	Oct 02 '26	Option Exercise	0.00	27	0	1,467	Oct 05 05:00 PM
Minor Lloyd	Director	Aug 03 '26	Sale	203.34	593	120,581	3,282	Aug 05 04:03 PM
Minor Lloyd	Director	Aug 04 '26	Sale	200.96	593	119,169	2,689	Aug 05 04:03 PM
Minor Lloyd	Director	Aug 04 '26	Proposed Sale	200.96	593	119,169		Aug 04 11:22 AM
Minor Lloyd	Director	Aug 03 '26	Proposed Sale	203.34	593	120,581		Aug 03 01:02 PM
Pangalos Menelas N	Director	Jun 09 '26	Option Exercise	0.00	2,370	0	2,370	Jun 11 05:21 PM
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	0.00	939	0	6,820	May 05 04:11 PM
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	0.00	181	0	1,396	Apr 03 04:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	195.03	3	585	19,611	Feb 17 08:16 PM
Viehbacher Christopher	President and CEO	Feb 06 '26	Option Exercise	0.00	24,461	0	36,548	Feb 10 05:06 PM
Singhal Priya	Head of Development	Feb 06 '26	Option Exercise	0.00	6,900	0	12,115	Feb 10 05:05 PM
Singhal Priya	Head of Development	Feb 09 '26	Sale	199.83	2,660	531,548	8,043	Feb 10 05:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 06 '26	Option Exercise	0.00	8,725	0	21,016	Feb 10 05:03 PM
Kramer Robin	Chief Financial Officer	Feb 06 '26	Option Exercise	0.00	5,003	0	12,535	Feb 10 05:02 PM
Keeney Adam	Head of Corporate Development	Feb 06 '26	Option Exercise	0.00	5,080	0	6,875	Feb 10 05:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 06 '26	Option Exercise	0.00	6,889	0	11,786	Feb 10 05:00 PM
Grogan Jane	Head of Research	Feb 06 '26	Option Exercise	0.00	3,258	0	4,642	Feb 10 04:59 PM
Gregory Ginger	EVP, Human Resources	Feb 06 '26	Option Exercise	0.00	7,183	0	23,491	Feb 10 04:58 PM
Godbout Sean	Chief Accounting Officer	Feb 06 '26	Option Exercise	0.00	1,079	0	1,395	Feb 10 04:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 06 '26	Option Exercise	0.00	9,046	0	43,321	Feb 10 04:55 PM
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	199.83	2,660	531,548		Feb 09 10:14 AM
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

PresidentMr. Christopher A. Viehbacher

Executive VP & CFOMs. Robin C. Kramer

Executive VP and Head of Pharmaceutical Operations & TechnologyMs. Nicole Murphy

M.P.H.Dr. Priya Singhal M.D.

VPMr. Sean Godbout

Open in Screener

VSTM

Verastem Inc

10.04

Oct 23 • 3:59 PM ET -0.02 (-0.20%)

10.04

Aftermarket • 7:53 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ERAS RVMD BBOT IMRX CELC KURA ORIC ELVN ZNTL CRDF

| Held by: XBI VTI IWM IWO VXF BBP VTWO FESM IWC IDNA

Index	RUT
Market Cap	1.22B
Enterprise Value	1.17B
Income	-202.70M
Sales	87.53M
Book/sh	0.55
Cash/sh	1.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	102
IPO	Jan 27, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	13.94
P/B	18.17
P/C	8.95
P/FCF	-
EV/EBITDA	-
EV/Sales	13.34
Quick Ratio	2.22
Current Ratio	2.25
Debt/Eq	1.69
LT Debt/Eq	1.57
Option/Short	Yes / Yes

EPS (ttm)	-2.46
EPS next Y	-1.57
EPS next Q	-0.47
EPS this Y	46.10%
EPS next Y	3.85%
EPS next 5Y	21.89%
EPS past 3/5Y	12.90% 10.63%
Sales past 3/5Y	- 10.80%
EPS Y/Y TTM	24.87%
Sales Y/Y TTM	3995.74%
EPS Q/Q	44.57%
Sales Q/Q	1775.43%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	18.70% 75.17%

Insider Own	9.46%
Insider Trans	-0.64%
Inst Own	77.88%
Inst Trans	10.33%
ROA	-100.65%
ROE	-471.16%
ROIC	-157.89%
Gross Margin	86.35%
Oper. Margin	-182.57%
Profit Margin	-231.59%
SMA20	19.24%
SMA50	27.49%
SMA200	64.42%
Trades

Shs Outstand	121.50M
Shs Float	110.01M
Short Float	13.60%
Short Ratio	4.75
Short Interest	14.96M
52W High	10.82 -7.22%
52W Low	3.43 192.71%
Volatility	8.03% 9.40%
ATR (14)	0.74
RSI (14)	67.24
Beta	0.47
Rel Volume	1.19
Avg Volume	3.15M
Volume	3,762,163

Perf Week	16.07%
Perf Month	28.72%
Perf Quarter	65.13%
Perf Half Y	69.88%
Perf YTD	30.05%
Perf Year	28.55%
Perf 3Y	51.66%
Perf 5Y	-67.19%
Perf 10Y	-40.24%
Recom	1.00
Target Price	17.22
Prev Close	10.06
Price	10.04
Change %	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-26	Initiated	Wolfe Research	Outperform
Mar-12-26	Resumed	BTIG Research	Buy	$19
Feb-04-26	Initiated	H.C. Wainwright	Buy	$18
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17

Show Previous Ratings

Oct-22-26 07:30AM	Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 (Business Wire) +9.23%
Oct-15-26 05:00PM	VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes (Stocktwits) +19.71% -6.28%
12:22PM	Verastems KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC (Clinical Trials Arena)
Oct-14-26 11:00AM	Verastem cancer drug shows early promise in small study (BioPharma Dive)
09:46AM	Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug (Barrons.com)
07:42AM	Loading…
07:42AM	Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know (Stocktwits)
06:04AM	Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (Business Wire)
06:01AM	Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan (Business Wire)
06:00AM	VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) (Business Wire)
Oct-11-26 10:17PM	Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates The Weeks Biotech Watchlist (Stocktwits)
Oct-05-26 04:02PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-02-26 07:30AM	Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 (Business Wire)
Sep-28-26 04:10PM	Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
08:00AM	KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 (PR Newswire)
Sep-25-26 08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
08:30AM	Loading…
Sep-24-26 08:30AM	Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting (Business Wire)
Sep-08-26 07:30AM	Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers (Business Wire)
Sep-02-26 07:30AM	Verastem Oncology to Participate in Upcoming September Investor Conferences (Business Wire) +5.39%
Aug-07-26 01:10AM	Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ... (GuruFocus.com) +14.04%
Aug-06-26 04:19PM	Verastem: Q2 Earnings Snapshot (Associated Press)
04:01PM	Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-28-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer (Business Wire)
Jul-23-26 07:30AM	Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jul-22-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer (Business Wire)
Jul-02-26 04:30PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.76%
Jun-23-26 04:01PM	VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors (Business Wire) -8.55%
Jun-17-26 07:30AM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer (Business Wire)
Jun-16-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer (Business Wire)
Jun-15-26 04:01PM	Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program (Business Wire)
Jun-03-26 08:10PM	VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug Retail Eyes The Next Keytruda (Stocktwits) +6.63%
07:30AM	Loading…
May-27-26 07:30AM	Verastem Oncology to Present at Jefferies Healthcare Conference (Business Wire)
May-26-26 07:30AM	Verastem Oncology Appoints Michael P. Bailey to its Board of Directors (Business Wire)
May-12-26 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire) -5.12%
May-08-26 07:30AM	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer (Business Wire) -13.60%
May-07-26 05:16PM	Verastem: Q1 Earnings Snapshot (Associated Press) -5.82%
04:01PM	Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Apr-30-26 07:30AM	Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Apr-23-26 07:30AM	Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-10-26 07:00AM	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire) -5.01%
Apr-02-26 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-17-26 06:03PM	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
04:44PM	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
Mar-05-26 12:03AM	Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com) +5.85%
Mar-04-26 08:48PM	Verastem Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:20PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Feb-18-26 07:30AM	Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
Feb-17-26 12:00PM	What Makes Verastem (VSTM) a New Buy Stock (Zacks)
Feb-16-26 01:02AM	Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Oct 01 '26	Sale	8.00	44,121	352,968	652,712	Oct 02 05:15 PM
Calkins Daniel	Chief Financial Officer	Oct 01 '26	Sale	8.00	2,566	20,528	123,781	Oct 02 05:15 PM
Dan Paterson	Officer, Director	Oct 01 '26	Proposed Sale	8.00	44,121	353,047		Oct 01 06:55 PM
Calkins Daniel	Chief Financial Officer	Sep 21 '26	Sale	7.70	55	424	118,014	Sep 23 08:10 PM
Paterson Dan	President and CEO	Aug 03 '26	Sale	5.81	1,302	7,565	589,940	Aug 05 04:37 PM
Gagnon Robert E.	Director	Jul 23 '26	Proposed Sale	5.89	31,924	188,032		Jul 23 04:32 PM
Gagnon Robert E.	Director	Jun 25 '26	Proposed Sale	4.21	21,492	90,481		Jun 25 04:01 PM
Paterson Dan	President and CEO	Jun 22 '26	Sale	4.18	20,871	87,241	591,242	Jun 24 04:45 PM
Calkins Daniel	Chief Financial Officer	Jun 22 '26	Sale	4.18	4,089	17,089	117,238	Jun 24 04:44 PM
Dan Paterson	Officer, Director	Jun 22 '26	Proposed Sale	4.18	20,871	87,241		Jun 22 07:50 PM
Gagnon Robert E.	Director	May 27 '26	Proposed Sale	4.36	20,103	87,649		May 27 04:47 PM
Paterson Dan	President and CEO	May 04 '26	Sale	5.82	806	4,691	612,113	May 06 04:01 PM
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

PresidentMr. Daniel W. Paterson

Chief Financial OfficerMr. Daniel Calkins

Ph.D.Dr. Michael Glen Kauffman M.D.

Co-Founder & Chair of Scientific Advisory BoardDr. Robert A. Weinberg Ph.D.

Ph.D.Dr. Michelle Detwiler M.D.

Open in Screener

FBIO

Fortress Biotech Inc

1.93

Oct 23 • 3:59 PM ET -0.06 (-3.02%)

1.90

Aftermarket • 7:30 PM ET -0.03 (-1.55%)

Healthcare Biotechnology USA Micro NASD

FBIO Fortress Biotech Inc daily Stock Chart

Peers: VRCA PTHS SLGL ARQT ROIV HRTX BFRI EOLS ETON AYTU

| Held by: VTI VXF IWC BSVO AVSC

Index	-
Market Cap	64.37M
Enterprise Value	-36.94M
Income	103.37M
Sales	68.47M
Book/sh	4.93
Cash/sh	5.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	78
IPO	Nov 17, 2011

P/E	0.73
Forward P/E	-
PEG	-
P/S	0.94
P/B	0.39
P/C	0.33
P/FCF	0.54
EV/EBITDA	-
EV/Sales	-0.54
Quick Ratio	3.83
Current Ratio	3.96
Debt/Eq	0.32
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	2.66
EPS next Y	-1.00
EPS next Q	-0.27
EPS this Y	3742.86%
EPS next Y	-139.22%
EPS next 5Y	-
EPS past 3/5Y	83.35% 62.98%
Sales past 3/5Y	-5.83% 6.77%
EPS Y/Y TTM	401.39%
Sales Y/Y TTM	15.46%
EPS Q/Q	-117.40%
Sales Q/Q	14.04%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	60.00% 2.28%

Insider Own	30.90%
Insider Trans	0.00%
Inst Own	22.65%
Inst Trans	2.99%
ROA	46.92%
ROE	107.48%
ROIC	53.19%
Gross Margin	58.88%
Oper. Margin	-42.86%
Profit Margin	150.97%
SMA20	-4.51%
SMA50	-19.57%
SMA200	-32.04%
Trades

Shs Outstand	33.31M
Shs Float	23.04M
Short Float	21.26%
Short Ratio	11.38
Short Interest	4.90M
52W High	4.53 -57.40%
52W Low	1.83 5.46%
Volatility	3.58% 4.08%
ATR (14)	0.09
RSI (14)	34.33
Beta	1.27
Rel Volume	0.52
Avg Volume	430.48K
Volume	223,625

Perf Week	3.21%
Perf Month	-15.35%
Perf Quarter	-40.98%
Perf Half Y	-17.17%
Perf YTD	-47.27%
Perf Year	-23.41%
Perf 3Y	10.92%
Perf 5Y	-95.71%
Perf 10Y	-95.11%
Recom	1.00
Target Price	5.00
Prev Close	1.99
Price	1.93
Change %	-3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Sep-08-26 04:05PM	Journey Medical Corporation to Participate in September 2026 Investor Conferences (GlobeNewswire)
08:00AM	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-13-26 05:05PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press) +8.36%
04:05PM	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-26 04:01PM	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.36%
08:30AM	Loading…
Aug-05-26 08:30AM	Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
Jul-27-26 08:00AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing (GlobeNewswire)
May-19-26 04:45PM	Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-18-26 08:30AM	Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-14-26 04:50PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press)
04:10PM	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-26 04:01PM	Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-06-26 04:01PM	Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 (GlobeNewswire) -5.88%
May-04-26 08:30AM	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-21-26 08:30AM	Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi (GlobeNewswire)
05:46PM	Loading…
Mar-31-26 05:46PM	Fortress Biotech: Q4 Earnings Snapshot (Associated Press) -11.47%
04:05PM	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-30-26 04:05PM	Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Mar-25-26 04:01PM	Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-26 08:30AM	Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 (GlobeNewswire)
Feb-24-26 08:53AM	Fortress Biotechs Cyprium enters agreement to sell PRV for $205M (TipRanks)
Feb-23-26 09:24AM	UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
08:30AM	Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
Jan-14-26 06:06AM	Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease (Pharmaceutical Business Review) -15.90%
Jan-13-26 07:45AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States (GlobeNewswire) -7.14%
Dec-15-25 08:00AM	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission (GlobeNewswire) +13.31%
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire)
09:40AM	Loading…
Nov-14-25 09:40AM	Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates (Zacks) +5.22%
08:40AM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 08:15AM	Kamada (KMDA) Misses Q3 Earnings Estimates (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)

Show Previous News

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Executive ChairmanDr. Lindsay Allan Rosenwald M.D.

CFO & Head of Corporate DevelopmentMr. David Jin

Chief Strategy OfficerDr. Xiaoqin Lu M.D.

J.D.Mr. Michael S. Weiss Esq.

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your Finviz experience